Brief: Moleculin Biotech Reports Second Quarter 2026 Financial Results And Highlights Continued Advancement Of Pivotal Miracle Trial
14/08/2026 13:50
BRIEF-Moleculin Biotech Reports Second Quarter 2026 Financial Results And Highlights Continued Advancement Of Pivotal Miracle Trial Aug 14 (Reuters) - Moleculin Biotech Inc MBRX.O:
MOLECULIN BIOTECH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS CONTINUED ADVANCEMENT OF PIVOTAL MIRACLE TRIAL
Source text: ID:nGNXdkBRf
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM